Multiple Options Mean More Time for Patients With Indolent Lymphoma
June 21st 2022The treatment landscape for relapsed/refractory MZL and follicular lymphoma (FL) is shifting from intravenous chemotherapy and monoclonal antibodies to oral oncolytic therapy or CD19-directed chimeric antigen receptor (CAR) T-cell therapy.
Read More
Opinion: The FDA is in a Hole With MOU on Compounding Medications—It Should Stop Digging
June 21st 2022Congress expected the FDA to draft a memorandum of understanding on interstate distributions of compounded medications that states would be willing to sign, but that’s not what the agency did.
Read More
Investigators Report Series of Substates that Reprogram IgG to 1-Step Synthesis of gsADCs
June 20th 2022Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.
Read More